Skip to main content

Promis Neurosciences Inc(PMN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.95
Day High2.08
Open:1.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
GlobeNewswire
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
GlobeNewswire
ProMIS Announces Completion of Continuance
GlobeNewswire
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
GlobeNewswire
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
GlobeNewswire
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

Profile

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.